GlassScriptPhysician profile
Gloria Park
NPI 1336770205
$5,026.60
in general payments reported to CMS, 2019-2025
21 companies · $708 in 2025
The $708 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,430 · 2022: $1,058 · 2023: $1,150 · 2024: $681 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,539.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,150.55 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $691.49 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $391.32 | 2021-2025 | Invega Sustenna, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $387.36 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $346.52 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $327.81 | 2021-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $270.87 | 2021-2023 | Ingrezza |
| Lundbeck LLC | $256.10 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $215.44 | 2021-2025 | Qelbree |
| Sunovion Pharmaceuticals INC. | $214.36 | 2021-2022 | |
| Axsome Therapeutics, INC. | $130.79 | 2023-2024 | Auvelity |
| Si-Bone, INC. | $130.73 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $117.73 | 2022-2024 | Austedo, Austedo Xr |
| Corium, LLC | $90.30 | 2022-2023 | Azstarys |
| Eisai INC. | $69.77 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $48.89 | 2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $47.21 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $45.85 | 2022-2023 | Belsomra |
| E.R. Squibb & Sons, L.L.C. | $33.74 | 2025 | Cobenfy |
| Tris Pharma INC | $30.66 | 2023-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $29.11 | 2021-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gloria Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.